New combo shows promise for melanoma patients who failed standard treatment
Disease control
Completed
This study tested a new drug combination for people with advanced melanoma that had stopped responding to standard immunotherapy. The treatment involved injecting BO-112 directly into tumors along with pembrolizumab given through a vein. The goal was to see if the combination cou…
Phase: PHASE2 • Sponsor: Highlight Therapeutics • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC